Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FRLN

Freeline Therapeutics (FRLN) Stock Price, News & Analysis

Freeline Therapeutics logo

About Freeline Therapeutics Stock (NASDAQ:FRLN)

Key Stats

Today's Range
$6.48
$6.48
50-Day Range
$6.43
$6.49
52-Week Range
$2.11
$8.74
Volume
N/A
Average Volume
12,055 shs
Market Capitalization
$28.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50
Consensus Rating
Hold

Company Overview

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Receive FRLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FRLN Stock News Headlines

Elon Musk has put himself in their crosshairs
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
Acquisition of Freeline by Syncona Becomes Effective
Acquisition of Freeline by Syncona Becomes Effective
Freeline Shareholders Approve Acquisition by Syncona
Freeline Therapeutics Holdings plc (FRLN)
See More Headlines

FRLN Stock Analysis - Frequently Asked Questions

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($12.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($15.20) by $2.30.

Shares of Freeline Therapeutics reverse split on the morning of Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Freeline Therapeutics (FRLN) raised $126 million in an initial public offering on Friday, August 7th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Freeline Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Jabil (JBL), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/09/2021
Today
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:FRLN
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.50
High Stock Price Target
$6.50
Low Stock Price Target
$6.50
Potential Upside/Downside
+0.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-88,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$12.07 per share

Miscellaneous

Free Float
4,259,000
Market Cap
$28.12 million
Optionable
Not Optionable
Beta
0.66
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:FRLN) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners